Lumida
/PRME
⌘K
Prime Medicine Inc

Prime Medicine Inc

PRME
$3.13USD-6.57%-0.22 today

MARKET CAP

567.7M

P/E (TTM)

FWD P/E

DAY RANGE

$3 – $3

52W RANGE

$3
$7

AI Summary

Stalk
Buy NowMedium

PRME is in an Early Stage 1 consolidation range after a prolonged downtrend, with the 9 and 21 EMAs having repaired and turned slightly upward. The Bullish Pivot Point pattern signals failed downside control and structural repair, giving a bullish medium-term mean-reversion bias against a bearish secular trend. Execution favors a Buy Now stance on a pullback into the rising EMA support zone within the base.

  • Q2 revenue beat by 4.4% and EPS beat by 6.3%
  • Net loss narrowed 20% YoY to $42.1M
  • Earnings yield is negative and profitability remains weak
Full analysis →
Insider Trades6 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
May 21, 2025BuyPRMEAnn L. LeeChief Technical Officer100,000$1.13$567.7M-54.90%+17.23%$113.0KBuy Now
May 21, 2025BuyPRMEAllan ReineChief Executive Officer125,000$1.18$567.7M-54.90%+17.23%$147.2KBuy Now
May 20, 2025BuyPRMERichard BrudnickChief Business Officer20,000$1.19$567.7M-54.90%+17.23%$23.8KBuy Now
Oct 8, 2024SellPRMEKeith Michael Gottesdiener453,850$3.78$567.7M-54.90%+17.23%$1.7M+0.00%Buy Now
Jun 5, 2024SellPRMEKeith Michael Gottesdiener500,000$6.58$567.7M-54.90%+17.23%$3.3M+0.00%Buy Now
Nov 11, 2023SellPRMEKeith Michael Gottesdiener12,500$6.80$567.7M-54.90%+17.23%$85.1K-0.48%Buy Now